Incyte Corporation (INCY) Covered Calls
Incyte Corporation is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company specializes in identifying and inhibiting specific enzymes and biological pathways to treat serious medical conditions, with a robust portfolio and pipeline spanning oncology, hematology, and inflammation & autoimmunity.
You can sell covered calls on Incyte Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for INCY (prices last updated Thu 1:00 PM ET):
| Incyte Corporation (INCY) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 92.52 | +0.28 | 92.50 | 92.64 | 481K | 14 | 18 |
| Covered Calls For Incyte Corporation (INCY) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 92.5 | 0.05 | 92.59 | -0.1% | -18.3% | |
| Apr 17 | 95 | 2.40 | 90.24 | 2.7% | 32.9% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Incyte Corporation (INCY) operates a vertically integrated biopharmaceutical model, taking candidates from initial drug discovery through clinical trials and global commercialization. Its scientific foundation is built on deep expertise in medicinal chemistry and biology, particularly regarding JAK (Janus kinase) inhibitors. Its flagship product, Jakafi (ruxolitinib), has established the company as a leader in treating myeloproliferative neoplasms, while its dermatological franchise, led by Opzelura, marks a strategic expansion into inflammation and autoimmune skin conditions.
The company’s growth strategy centers on a dual approach: maximizing the potential of its existing commercial portfolio while aggressively investing in a diverse R&D pipeline. Through both internal discovery and strategic acquisitions—such as the purchase of Escient Pharmaceuticals—Incyte continuously bolsters its capabilities in addressing high-unmet-need areas, aiming to provide first-in-class or best-in-class medicines for both large and orphan patient populations.
Competitive Landscape
Incyte competes in the highly innovative and competitive biotechnology and pharmaceutical sectors. Its primary optionable peers include:
- AbbVie Inc. (ABBV): A large-cap biopharma powerhouse that competes across oncology and immunology, possessing vast resources for drug development and commercialization.
- Biogen Inc. (BIIB): A major biopharmaceutical entity that, while focused on neurology, competes for talent, investment, and market presence in the broader medical sector.
- BioMarin Pharmaceutical Inc. (BMRN): A specialized biotech firm focused on rare genetic diseases, often competing for the same R&D investment interest.
- Neurocrine Biosciences, Inc. (NBIX): A biotech leader in endocrine and neurological disorders that occupies a similar mid-to-large-cap space in the healthcare market.
Strategic Outlook and Innovation
Incyte’s strategic outlook is defined by its pursuit of "Solving On"—the relentless investigation of novel biological pathways. As key assets approach potential patent cliffs in the coming years, the company is prioritizing pipeline diversification and geographic expansion to maintain revenue growth. It is increasingly leveraging advanced technologies, including artificial intelligence in drug discovery, to shorten development cycles and improve success rates in clinical trials.
Innovation is at the core of Incyte’s identity. By focusing on precision medicine and targeted therapies, the company seeks to move beyond traditional broad-spectrum treatments, offering more effective, personalized options for patients. This commitment to rigorous R&D, combined with a disciplined approach to strategic collaborations, positions Incyte to remain a key player in the evolving landscape of specialized medicine.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | PL covered calls | |
| 2. | SLV covered calls | 7. | TSLA covered calls | 2. | NVCR covered calls | |
| 3. | SPY covered calls | 8. | SOFI covered calls | 3. | FLY covered calls | |
| 4. | EEM covered calls | 9. | EWZ covered calls | 4. | AAOI covered calls | |
| 5. | IBIT covered calls | 10. | FXI covered calls | 5. | ONDS covered calls | |
Want more examples? INCR Covered Calls | INDA Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
